Woven EndoBridge (WEB; Sequent Medical) treatment is an innovative endovascular approach
for treatment of wide-neck bifurcation aneurysms. Initial studies have shown high
safety with good efficacy at short term confirmed by trials conducted in United States
(WEB-Intrasaccular Therapy) and in Europe (WEB Clinical Assessment of Intrasaccular
Aneurysm Therapy [WEBCAST], French Observatory, and WEBCAST-2).To report the 2-yr
clinical and anatomical results of WEB treatment in the combined population of 3 European
trials.In a French Observatory, 2-yr clinical and anatomical data were collected.
In WEBCAST and WEBCAST-2, 2-yr follow-up was optional, and data were collected when
follow-up was performed. Aneurysm occlusion was evaluated using a 3-grade scale: complete
occlusion, neck remnant, and aneurysm remnant.The population for safety was 138/168
patients (82.1%), including 89 females (64.5%), with mean age of 55.5 ± 10.2 yr. The
population for efficacy was 121/169 aneurysms (71.6%). Aneurysm locations were middle
cerebral artery in 65/121 aneurysms (53.7%), anterior-communicating artery in 25/121
(20.7%), basilar artery in 17/121 (14.0%), and internal carotid artery terminus in
14/121 (11.6%). No clinically relevant adverse events occurred between years 1 and
2. At 2 yr, complete occlusion was observed in 62/121 (51.2%) aneurysms, neck remnant
in 36/121 (29.8%) aneurysms, and aneurysm remnant in 23/121 (19.0%) aneurysms. The
global retreatment rate at 2 yr was 9.3%.This analysis confirms the high safety profile
of WEB treatment at 2 yr. Aneurysm occlusion is generally stable at 2 yr, and the
retreatment rate between 1 yr and 2 yr is low (2.0%).
